A gap of 130 million courses of treatment!

According to the latest report from Yaorongyun, the latest data from the MPP (Medicines Patent Pool) shows that China's Desano, Huahai Pharmaceutical, Puluo Pharmaceutical, Fosun Pharmaceutical, and Jiuzhou Pharmaceutical have obtained relevant authorizations to sell in low- and middle-income countries.
Pfizer's nematevir-related APIs , please note that they do not cover the Chinese market
.

What does it mean to be licensed by the MPP patent pool?

The production capacity of Pfizer’s oral specific drug Paxlovid currently has a large gap in production capacity.
This year, it can only provide 120 million courses of treatment.
According to Pfizer’s own expectations, in 2022, about 250 million people in the world will need antiviral drugs (maybe more or less) , then there is at least a gap of about 130 million courses of treatment
.

Although Pfizer has committed to supply 10 million courses of treatment to low-income countries out of its 120 million production capacity, the price of supply is currently $530 per course of treatment to the U.
S.
government, and the price for some rich countries may be will further increase to close to $700, so most of the product will go to upper-middle-income countries
.

In this way, the importance of the MPP patent pool is highlighted
.

As of early 2022, the areas of authorization signed by MPP include 13 anti-HIV drugs, 1 anti-HIV technology platform, 3 anti-hepatitis C drugs, 1 tuberculosis therapy, 2 long-acting technologies, 2 anti-COVID-19 drugs and 1 new crown antibody detection
.

Being selected into the MPP patent pool of Pfizer Paxlovid is not only a recognition of the capability of M of domestic CDMO companies, but also provides a platform for better going overseas in the future.
Long-term benefits > short-term, there are no more than 30 domestic companies with MPP experience
.

The impact on domestic authorized pharmaceutical companies has been sorted out, and the impact is as follows:

1.
MPP's screening criteria for applying for generic drug companies and requirements for drug quality have built a good platform for Chinese pharmaceutical companies to improve their R&D and production capacity and test the international market
.

2.
MPP provides Chinese pharmaceutical companies with an opportunity to carry out technical cooperation with outstanding multinational pharmaceutical companies.
Obtaining MPP authorization is also an important manifestation of the company's global compliance production capacity
.

3.
In the near future, more innovative drugs may be included in the scope of MPP authorization, and biological drugs may learn from the MPP licensing model to meet the needs of low- and middle-income countries for biosimilars.
MPP can become a platform for more Chinese pharmaceutical companies to enter the international market.
One of the channels to actively participate in international competition
.

4.
In the longer run, with the continuous improvement of technological innovation capabilities of Chinese enterprises, there will be more and more global new drugs independently developed by Chinese pharmaceutical companies.
As patent holders, Chinese pharmaceutical companies can also fully utilize the mature MPP.
The platform seeks overseas cooperation and develops international markets
.

After this incident, these CDMOs will undoubtedly gain more right to speak in future negotiations with international MNCs
.